Oppenheimer initiated coverage of Guardian Pharmacy (GRDN) with an Outperform rating and $30 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy price target raised to $30 from $28 at Truist
- Guardian Pharmacy management to meet with Truist
- Guardian Pharmacy Highlights Strategic Initiatives in ALF Market
- Guardian Pharmacy Services Reports Strong Q2 2025 Results
- Guardian Pharmacy reports Q2 adjusted EPS 23c, two estimates 22c